Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Liabilities and Shareholders Equity (2021 - 2025)

Medicinova (MNOV) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $45.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity changed N/A to $45.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $195.4 million, a N/A change, with the full-year FY2025 number at $45.6 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $45.6 million for Q4 2025 at Medicinova, down from $47.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $96.1 million in Q1 2021 to a low of $45.6 million in Q4 2025.
  • A 5-year average of $70.2 million and a median of $68.4 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 11.58% in 2024, then dropped 18.14% in 2025.
  • Medicinova's Liabilities and Shareholders Equity stood at $87.4 million in 2021, then fell by 10.31% to $78.4 million in 2022, then dropped by 15.46% to $66.3 million in 2023, then fell by 12.3% to $58.1 million in 2024, then fell by 21.54% to $45.6 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Liabilities and Shareholders Equity are $45.6 million (Q4 2025), $47.6 million (Q3 2025), and $49.8 million (Q2 2025).